Texas Biomed is the only independent nonprofit infectious disease research institute in the U.S. that combines high-level biocontainment labs for infectious disease and biodefense research, being a federally-designated National Primate Research Center with more than 80 years of discoveries advancing diagnostics, vaccines, and therapies.
1941
74-1109630
$234.6 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Bringing together leaders to discuss innovations in biomedical science.
Impact stories highlighting the role of science in transforming lives.
Innovative research in infectious diseases.
First COVID-19 Vaccine
Advanced the development of the first COVID-19 vaccine.
First Ebola Treatment
Developed the first treatment for Ebola.
First Hepatitis-C Therapy
Developed the first therapy for Hepatitis-C.
Focuses on prevention and treatment of infectious diseases.
Learn MoreOverall Score
65
32
/100
Program Expense Ratio
52.92%
4
/20
Program Revenue Growth
-77.65%
2
/20
Leverage Ratio
0.414
10
/20
Working Capital Ratio
1.896
14
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 55.3M | 85.02% |
Program Services | 4.929M | 7.58% |
Investment Income | 1.343M | 2.06% |
Sales of Non-Inventory Assets | 2.063M | 3.17% |
Other Notable Sources | 856K | 1.32% |
Total Revenue | 65.05M | 100.00% |
Med Research
Medical Conditions ResearchMed Research
Medical Conditions ResearchMed Research
Medical Conditions ResearchMed Research
Medical Conditions ResearchMed Research
Medical Conditions Research